Immuneering Signs Clinical Supply Agreement With Regeneron To Evaluate IMM-1-104 Plus Libtayo
Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...
Hosted on MSN17h
Regeneron Stock Down 30% Over Past 6 Months: Leerink Sees Buying Opportunity, Retail's On The Same Page
Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...
Immuneering and Regeneron partner on lung cancer trial
CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...
Jim Cramer: Buy American Express (AXP) on Travel Strength
We recently published a list of Jim Cramer Discusses These 10 Stocks & President Trump’s Tariffs. In this article, we are ...
CoreLogic: Home Price Growth Ticks up Slightly in December
CoreLogic®, a leading global property information, analytics and data-enabled solutions provider, today released the ...